Cart
sales@molnova.com
TX1-85-1
CAS No. 1603845-32-4
TX1-85-1( —— )
Catalog No. M23702 CAS No. 1603845-32-4
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 401 | In Stock |
|
| 50MG | 591 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTX1-85-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
-
DescriptionTX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. TX1-85-1 is an irreversible Her3 inhibitor (IC50: 23 nM). TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.
-
In VitroTX1-85-1 possesses an anti-proliferation EC50s of 9.9, 11.5, and 16.9 μM for Ovcar8, HCC827 GR6, and PC9 GR4 cells, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorErbB3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1603845-32-4
-
Formula Weight580.68
-
Molecular FormulaC32H36N8O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:3.85 mg/mL (6.63 mM; Need ultrasonic)
-
SMILESCC(N1CCN(C2CCC(N3N=C(C4=CC(NC(C=C)=O)=C(OC5=CC=CC=C5)C=C4)C6=C3N=CN=C6N)CC2)CC1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Xie T, et al. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014 Dec;10(12):1006-12.
molnova catalog
related products
-
PF-06747775
A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.
-
PD 174265
PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
